Literature DB >> 21730228

Screening for HIV infection: a healthy, "low-risk" 42-year-old man.

Howard Libman1.   

Abstract

Human immunodeficiency virus (HIV) infection meets many, if not all, of the established criteria that justify routine screening, and screening for HIV infection can be cost-effective depending on the population studied. In 2006, the Centers for Disease Control and Prevention recommended that HIV screening be included as part of routine care for most of the adult US population, but implementation of this policy has been slow. Mr Y is a 42-year-old man at relatively low risk of HIV infection who was offered testing by his primary care physician but declined it. He does not consider HIV infection to be a realistic possibility given his behavioral history and does not understand the purpose of being tested. The discussion that follows addresses the rationale for HIV screening, its potential benefits and risks, current testing options, and barriers to incorporating it into routine care.

Entities:  

Mesh:

Year:  2011        PMID: 21730228     DOI: 10.1001/jama.2011.1016

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

1.  Electronic medical record alert increases HIV screening rates: the Foch hospital pilot POP-up project.

Authors:  Alexandre Vallée; Dimi Sveltlane; Julie Trichereau; Stéphane Neveu; Erwan Fourn; Catherine Majerholc; Philippe Lesprit; Laurence Mazaux; Seheno Harijaona Henintsoa; Grazyna Matejczuk; Marc Vasse; David Zucman
Journal:  BMC Health Serv Res       Date:  2022-06-16       Impact factor: 2.908

Review 2.  Misdiagnosis of Treatable Stroke Mimic: The Case for HIV Screening in Practice Guidelines.

Authors:  Pasquale F Finelli
Journal:  Neurohospitalist       Date:  2013-10

3.  Use of an electronic medical record reminder improves HIV screening.

Authors:  Colleen Kershaw; Jessica L Taylor; Gary Horowitz; Diane Brockmeyer; Howard Libman; Gila Kriegel; Long Ngo
Journal:  BMC Health Serv Res       Date:  2018-01-10       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.